Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients
The nanoparticle complex of cholesteryl pullulan (CHP) and NY-ESO-1 antigen protein (CHP-NY-ESO-1) presents multiple epitope peptides to MHC class I and II pathways, leading to CD8 + and CD4 + T cell responses. Poly-ICLC is a synthetic, double-stranded RNA, an agonist of toll-like receptor (TLR)-3,...
Gespeichert in:
| Veröffentlicht in: | Cancer Immunology, Immunotherapy Immunotherapy, 2021-11, Vol.70 (11), p.3081-3091 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3091 |
|---|---|
| container_issue | 11 |
| container_start_page | 3081 |
| container_title | Cancer Immunology, Immunotherapy |
| container_volume | 70 |
| creator | Ishikawa, Takeshi Kageyama, Shinichi Miyahara, Yoshihiro Okayama, Tetsuya Kokura, Satoshi Wang, Linan Sato, Eiichi Yagita, Hideo Itoh, Yoshito Shiku, Hiroshi |
| description | The nanoparticle complex of cholesteryl pullulan (CHP) and NY-ESO-1 antigen protein (CHP-NY-ESO-1) presents multiple epitope peptides to MHC class I and II pathways, leading to CD8
+
and CD4
+
T cell responses. Poly-ICLC is a synthetic, double-stranded RNA, an agonist of toll-like receptor (TLR)-3, and a cytoplasmic receptor of melanoma differentiation-associated gene (MDA)-5. It should be a suitable immune adjuvant of cancer vaccine to overcome the inhibitory tumor microenvironment. We conducted a phase 1 clinical trial of CHP-NY-ESO-1 with poly-ICLC in patients with advanced or recurrent esophageal cancer. CHP-NY-ESO-1/poly-ICLC (μg/mg) was administered at a dose of 200/0.5 or 200/1.0 (cohorts 1 and 2, respectively) every 2 weeks for a total of six doses. The primary endpoints were safety and immune response. The secondary endpoint was tumor response. In total, 16 patients were enrolled, and six patients in each cohort completed the trial. The most common adverse event (AE) was injection site skin reaction (86.7%). No grade 3 or higher drug-related AEs were observed. No tumor responses were observed, and three patients (30%) had stable disease. The immune response was comparable between the two cohorts, and all patients (100%) achieved antibody responses with a median of 2.5 vaccinations. Comparing CHP-NY-ESO-1 alone to the poly-ICLC combination, all patients in both groups exhibited antibody responses, but the titers were higher in the combination group. In a mouse model, adding anti-PD-1 antibody to the combination of CHP-NY-ESO-1/poly-ICLC suppressed the growth of NY-ESO-1-expressing tumors. Combining the vaccine with PD-1 blockade holds promise in human trials. |
| doi_str_mv | 10.1007/s00262-021-02892-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10991152</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2580827446</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-3cb35e59a99719459c4f4abdb0cc222bd08d59b235c7e902223bf894f45709873</originalsourceid><addsrcrecordid>eNp9UU1v1DAQtRAV3Rb-AAdkibOLP5v4hFBUaKUVrVQ4cLJsx9lNtbGDnexqfwF_mylbSrn0MBpr3pv3Rn4IvWX0jFFafSiU8nNOKGdQteZk9wItmBQwqhV7iRZUSEoqSuUxOinlDh6cav0KHQtRKcZpvUC_bm0Xpj22sYWaepfaPe6HYY4B51DGFEvAqcPN5Q35-oNc3F4ThrfW-x4IPg0Oeot3_bTGY9rsyVWzbHAfsW23NnqAUgYdP-cc4oRDSeParoLdYH8PZzzaqQekvEZHnd2U8Oahn6Lvny--NZdkef3lqvm0JF4KNhHhnVBBaat1xbRU2stOWtc66j3n3LW0bpV2XChfBU1hJFxXayCpiuq6Eqfo40F3nN0QWg_e2W7MmPvB5r1Jtjf_I7Ffm1XaGgY_x5jioPD-QSGnn3Mok7lLc45wtOGqpjWvpDwHFj-wfE6l5NA9WjBq7tMzh_QMpGf-pGd2sPTu6XGPK3_jAoI4EApAcRXyP-9nZH8DxMKm5A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2580827446</pqid></control><display><type>article</type><title>Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients</title><source>MEDLINE</source><source>SpringerNature Journals</source><source>PubMed Central</source><creator>Ishikawa, Takeshi ; Kageyama, Shinichi ; Miyahara, Yoshihiro ; Okayama, Tetsuya ; Kokura, Satoshi ; Wang, Linan ; Sato, Eiichi ; Yagita, Hideo ; Itoh, Yoshito ; Shiku, Hiroshi</creator><creatorcontrib>Ishikawa, Takeshi ; Kageyama, Shinichi ; Miyahara, Yoshihiro ; Okayama, Tetsuya ; Kokura, Satoshi ; Wang, Linan ; Sato, Eiichi ; Yagita, Hideo ; Itoh, Yoshito ; Shiku, Hiroshi</creatorcontrib><description>The nanoparticle complex of cholesteryl pullulan (CHP) and NY-ESO-1 antigen protein (CHP-NY-ESO-1) presents multiple epitope peptides to MHC class I and II pathways, leading to CD8
+
and CD4
+
T cell responses. Poly-ICLC is a synthetic, double-stranded RNA, an agonist of toll-like receptor (TLR)-3, and a cytoplasmic receptor of melanoma differentiation-associated gene (MDA)-5. It should be a suitable immune adjuvant of cancer vaccine to overcome the inhibitory tumor microenvironment. We conducted a phase 1 clinical trial of CHP-NY-ESO-1 with poly-ICLC in patients with advanced or recurrent esophageal cancer. CHP-NY-ESO-1/poly-ICLC (μg/mg) was administered at a dose of 200/0.5 or 200/1.0 (cohorts 1 and 2, respectively) every 2 weeks for a total of six doses. The primary endpoints were safety and immune response. The secondary endpoint was tumor response. In total, 16 patients were enrolled, and six patients in each cohort completed the trial. The most common adverse event (AE) was injection site skin reaction (86.7%). No grade 3 or higher drug-related AEs were observed. No tumor responses were observed, and three patients (30%) had stable disease. The immune response was comparable between the two cohorts, and all patients (100%) achieved antibody responses with a median of 2.5 vaccinations. Comparing CHP-NY-ESO-1 alone to the poly-ICLC combination, all patients in both groups exhibited antibody responses, but the titers were higher in the combination group. In a mouse model, adding anti-PD-1 antibody to the combination of CHP-NY-ESO-1/poly-ICLC suppressed the growth of NY-ESO-1-expressing tumors. Combining the vaccine with PD-1 blockade holds promise in human trials.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-021-02892-w</identifier><identifier>PMID: 33751208</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adjuvants, Immunologic - therapeutic use ; Adverse events ; Aged ; Aged, 80 and over ; Animals ; Antibodies ; Antigens, Neoplasm - immunology ; Antigens, Neoplasm - therapeutic use ; Cancer ; Cancer Research ; Cancer vaccines ; Cancer Vaccines - immunology ; Cancer Vaccines - therapeutic use ; Carboxymethylcellulose Sodium - analogs & derivatives ; Carboxymethylcellulose Sodium - therapeutic use ; CD4 antigen ; CD8 antigen ; Clinical trials ; Combined vaccines ; Double-stranded RNA ; Epitopes ; Esophageal cancer ; Esophageal Neoplasms - drug therapy ; Esophageal Neoplasms - immunology ; Esophagus ; Female ; Glucans - immunology ; Glucans - therapeutic use ; Humans ; Immunology ; Immunotherapy ; Interferon Inducers - immunology ; Interferon Inducers - therapeutic use ; Lymphocytes T ; Major histocompatibility complex ; Male ; Medicine ; Medicine & Public Health ; Melanoma ; Membrane Proteins - immunology ; Membrane Proteins - therapeutic use ; Mice ; Middle Aged ; Nanoparticles ; Oncology ; Original ; Original Article ; Patients ; PD-1 protein ; Poly I-C - immunology ; Poly I-C - therapeutic use ; Polylysine - analogs & derivatives ; Polylysine - immunology ; Polylysine - therapeutic use ; Toll-like receptors ; Tumor microenvironment ; Tumors ; Vaccines</subject><ispartof>Cancer Immunology, Immunotherapy, 2021-11, Vol.70 (11), p.3081-3091</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-3cb35e59a99719459c4f4abdb0cc222bd08d59b235c7e902223bf894f45709873</citedby><cites>FETCH-LOGICAL-c431t-3cb35e59a99719459c4f4abdb0cc222bd08d59b235c7e902223bf894f45709873</cites><orcidid>0000-0002-7682-3295</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10991152/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10991152/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,41488,42557,51319,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33751208$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ishikawa, Takeshi</creatorcontrib><creatorcontrib>Kageyama, Shinichi</creatorcontrib><creatorcontrib>Miyahara, Yoshihiro</creatorcontrib><creatorcontrib>Okayama, Tetsuya</creatorcontrib><creatorcontrib>Kokura, Satoshi</creatorcontrib><creatorcontrib>Wang, Linan</creatorcontrib><creatorcontrib>Sato, Eiichi</creatorcontrib><creatorcontrib>Yagita, Hideo</creatorcontrib><creatorcontrib>Itoh, Yoshito</creatorcontrib><creatorcontrib>Shiku, Hiroshi</creatorcontrib><title>Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients</title><title>Cancer Immunology, Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><addtitle>Cancer Immunol Immunother</addtitle><description>The nanoparticle complex of cholesteryl pullulan (CHP) and NY-ESO-1 antigen protein (CHP-NY-ESO-1) presents multiple epitope peptides to MHC class I and II pathways, leading to CD8
+
and CD4
+
T cell responses. Poly-ICLC is a synthetic, double-stranded RNA, an agonist of toll-like receptor (TLR)-3, and a cytoplasmic receptor of melanoma differentiation-associated gene (MDA)-5. It should be a suitable immune adjuvant of cancer vaccine to overcome the inhibitory tumor microenvironment. We conducted a phase 1 clinical trial of CHP-NY-ESO-1 with poly-ICLC in patients with advanced or recurrent esophageal cancer. CHP-NY-ESO-1/poly-ICLC (μg/mg) was administered at a dose of 200/0.5 or 200/1.0 (cohorts 1 and 2, respectively) every 2 weeks for a total of six doses. The primary endpoints were safety and immune response. The secondary endpoint was tumor response. In total, 16 patients were enrolled, and six patients in each cohort completed the trial. The most common adverse event (AE) was injection site skin reaction (86.7%). No grade 3 or higher drug-related AEs were observed. No tumor responses were observed, and three patients (30%) had stable disease. The immune response was comparable between the two cohorts, and all patients (100%) achieved antibody responses with a median of 2.5 vaccinations. Comparing CHP-NY-ESO-1 alone to the poly-ICLC combination, all patients in both groups exhibited antibody responses, but the titers were higher in the combination group. In a mouse model, adding anti-PD-1 antibody to the combination of CHP-NY-ESO-1/poly-ICLC suppressed the growth of NY-ESO-1-expressing tumors. Combining the vaccine with PD-1 blockade holds promise in human trials.</description><subject>Adjuvants, Immunologic - therapeutic use</subject><subject>Adverse events</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Antigens, Neoplasm - therapeutic use</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Cancer vaccines</subject><subject>Cancer Vaccines - immunology</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Carboxymethylcellulose Sodium - analogs & derivatives</subject><subject>Carboxymethylcellulose Sodium - therapeutic use</subject><subject>CD4 antigen</subject><subject>CD8 antigen</subject><subject>Clinical trials</subject><subject>Combined vaccines</subject><subject>Double-stranded RNA</subject><subject>Epitopes</subject><subject>Esophageal cancer</subject><subject>Esophageal Neoplasms - drug therapy</subject><subject>Esophageal Neoplasms - immunology</subject><subject>Esophagus</subject><subject>Female</subject><subject>Glucans - immunology</subject><subject>Glucans - therapeutic use</subject><subject>Humans</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Interferon Inducers - immunology</subject><subject>Interferon Inducers - therapeutic use</subject><subject>Lymphocytes T</subject><subject>Major histocompatibility complex</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Melanoma</subject><subject>Membrane Proteins - immunology</subject><subject>Membrane Proteins - therapeutic use</subject><subject>Mice</subject><subject>Middle Aged</subject><subject>Nanoparticles</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Patients</subject><subject>PD-1 protein</subject><subject>Poly I-C - immunology</subject><subject>Poly I-C - therapeutic use</subject><subject>Polylysine - analogs & derivatives</subject><subject>Polylysine - immunology</subject><subject>Polylysine - therapeutic use</subject><subject>Toll-like receptors</subject><subject>Tumor microenvironment</subject><subject>Tumors</subject><subject>Vaccines</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9UU1v1DAQtRAV3Rb-AAdkibOLP5v4hFBUaKUVrVQ4cLJsx9lNtbGDnexqfwF_mylbSrn0MBpr3pv3Rn4IvWX0jFFafSiU8nNOKGdQteZk9wItmBQwqhV7iRZUSEoqSuUxOinlDh6cav0KHQtRKcZpvUC_bm0Xpj22sYWaepfaPe6HYY4B51DGFEvAqcPN5Q35-oNc3F4ThrfW-x4IPg0Oeot3_bTGY9rsyVWzbHAfsW23NnqAUgYdP-cc4oRDSeParoLdYH8PZzzaqQekvEZHnd2U8Oahn6Lvny--NZdkef3lqvm0JF4KNhHhnVBBaat1xbRU2stOWtc66j3n3LW0bpV2XChfBU1hJFxXayCpiuq6Eqfo40F3nN0QWg_e2W7MmPvB5r1Jtjf_I7Ffm1XaGgY_x5jioPD-QSGnn3Mok7lLc45wtOGqpjWvpDwHFj-wfE6l5NA9WjBq7tMzh_QMpGf-pGd2sPTu6XGPK3_jAoI4EApAcRXyP-9nZH8DxMKm5A</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Ishikawa, Takeshi</creator><creator>Kageyama, Shinichi</creator><creator>Miyahara, Yoshihiro</creator><creator>Okayama, Tetsuya</creator><creator>Kokura, Satoshi</creator><creator>Wang, Linan</creator><creator>Sato, Eiichi</creator><creator>Yagita, Hideo</creator><creator>Itoh, Yoshito</creator><creator>Shiku, Hiroshi</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7682-3295</orcidid></search><sort><creationdate>20211101</creationdate><title>Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients</title><author>Ishikawa, Takeshi ; Kageyama, Shinichi ; Miyahara, Yoshihiro ; Okayama, Tetsuya ; Kokura, Satoshi ; Wang, Linan ; Sato, Eiichi ; Yagita, Hideo ; Itoh, Yoshito ; Shiku, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-3cb35e59a99719459c4f4abdb0cc222bd08d59b235c7e902223bf894f45709873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adjuvants, Immunologic - therapeutic use</topic><topic>Adverse events</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Antigens, Neoplasm - therapeutic use</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Cancer vaccines</topic><topic>Cancer Vaccines - immunology</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Carboxymethylcellulose Sodium - analogs & derivatives</topic><topic>Carboxymethylcellulose Sodium - therapeutic use</topic><topic>CD4 antigen</topic><topic>CD8 antigen</topic><topic>Clinical trials</topic><topic>Combined vaccines</topic><topic>Double-stranded RNA</topic><topic>Epitopes</topic><topic>Esophageal cancer</topic><topic>Esophageal Neoplasms - drug therapy</topic><topic>Esophageal Neoplasms - immunology</topic><topic>Esophagus</topic><topic>Female</topic><topic>Glucans - immunology</topic><topic>Glucans - therapeutic use</topic><topic>Humans</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Interferon Inducers - immunology</topic><topic>Interferon Inducers - therapeutic use</topic><topic>Lymphocytes T</topic><topic>Major histocompatibility complex</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Melanoma</topic><topic>Membrane Proteins - immunology</topic><topic>Membrane Proteins - therapeutic use</topic><topic>Mice</topic><topic>Middle Aged</topic><topic>Nanoparticles</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Patients</topic><topic>PD-1 protein</topic><topic>Poly I-C - immunology</topic><topic>Poly I-C - therapeutic use</topic><topic>Polylysine - analogs & derivatives</topic><topic>Polylysine - immunology</topic><topic>Polylysine - therapeutic use</topic><topic>Toll-like receptors</topic><topic>Tumor microenvironment</topic><topic>Tumors</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ishikawa, Takeshi</creatorcontrib><creatorcontrib>Kageyama, Shinichi</creatorcontrib><creatorcontrib>Miyahara, Yoshihiro</creatorcontrib><creatorcontrib>Okayama, Tetsuya</creatorcontrib><creatorcontrib>Kokura, Satoshi</creatorcontrib><creatorcontrib>Wang, Linan</creatorcontrib><creatorcontrib>Sato, Eiichi</creatorcontrib><creatorcontrib>Yagita, Hideo</creatorcontrib><creatorcontrib>Itoh, Yoshito</creatorcontrib><creatorcontrib>Shiku, Hiroshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology, Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ishikawa, Takeshi</au><au>Kageyama, Shinichi</au><au>Miyahara, Yoshihiro</au><au>Okayama, Tetsuya</au><au>Kokura, Satoshi</au><au>Wang, Linan</au><au>Sato, Eiichi</au><au>Yagita, Hideo</au><au>Itoh, Yoshito</au><au>Shiku, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients</atitle><jtitle>Cancer Immunology, Immunotherapy</jtitle><stitle>Cancer Immunol Immunother</stitle><addtitle>Cancer Immunol Immunother</addtitle><date>2021-11-01</date><risdate>2021</risdate><volume>70</volume><issue>11</issue><spage>3081</spage><epage>3091</epage><pages>3081-3091</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><abstract>The nanoparticle complex of cholesteryl pullulan (CHP) and NY-ESO-1 antigen protein (CHP-NY-ESO-1) presents multiple epitope peptides to MHC class I and II pathways, leading to CD8
+
and CD4
+
T cell responses. Poly-ICLC is a synthetic, double-stranded RNA, an agonist of toll-like receptor (TLR)-3, and a cytoplasmic receptor of melanoma differentiation-associated gene (MDA)-5. It should be a suitable immune adjuvant of cancer vaccine to overcome the inhibitory tumor microenvironment. We conducted a phase 1 clinical trial of CHP-NY-ESO-1 with poly-ICLC in patients with advanced or recurrent esophageal cancer. CHP-NY-ESO-1/poly-ICLC (μg/mg) was administered at a dose of 200/0.5 or 200/1.0 (cohorts 1 and 2, respectively) every 2 weeks for a total of six doses. The primary endpoints were safety and immune response. The secondary endpoint was tumor response. In total, 16 patients were enrolled, and six patients in each cohort completed the trial. The most common adverse event (AE) was injection site skin reaction (86.7%). No grade 3 or higher drug-related AEs were observed. No tumor responses were observed, and three patients (30%) had stable disease. The immune response was comparable between the two cohorts, and all patients (100%) achieved antibody responses with a median of 2.5 vaccinations. Comparing CHP-NY-ESO-1 alone to the poly-ICLC combination, all patients in both groups exhibited antibody responses, but the titers were higher in the combination group. In a mouse model, adding anti-PD-1 antibody to the combination of CHP-NY-ESO-1/poly-ICLC suppressed the growth of NY-ESO-1-expressing tumors. Combining the vaccine with PD-1 blockade holds promise in human trials.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>33751208</pmid><doi>10.1007/s00262-021-02892-w</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-7682-3295</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-7004 |
| ispartof | Cancer Immunology, Immunotherapy, 2021-11, Vol.70 (11), p.3081-3091 |
| issn | 0340-7004 1432-0851 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10991152 |
| source | MEDLINE; SpringerNature Journals; PubMed Central |
| subjects | Adjuvants, Immunologic - therapeutic use Adverse events Aged Aged, 80 and over Animals Antibodies Antigens, Neoplasm - immunology Antigens, Neoplasm - therapeutic use Cancer Cancer Research Cancer vaccines Cancer Vaccines - immunology Cancer Vaccines - therapeutic use Carboxymethylcellulose Sodium - analogs & derivatives Carboxymethylcellulose Sodium - therapeutic use CD4 antigen CD8 antigen Clinical trials Combined vaccines Double-stranded RNA Epitopes Esophageal cancer Esophageal Neoplasms - drug therapy Esophageal Neoplasms - immunology Esophagus Female Glucans - immunology Glucans - therapeutic use Humans Immunology Immunotherapy Interferon Inducers - immunology Interferon Inducers - therapeutic use Lymphocytes T Major histocompatibility complex Male Medicine Medicine & Public Health Melanoma Membrane Proteins - immunology Membrane Proteins - therapeutic use Mice Middle Aged Nanoparticles Oncology Original Original Article Patients PD-1 protein Poly I-C - immunology Poly I-C - therapeutic use Polylysine - analogs & derivatives Polylysine - immunology Polylysine - therapeutic use Toll-like receptors Tumor microenvironment Tumors Vaccines |
| title | Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T03%3A33%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20antibody%20immune%20response%20of%20CHP-NY-ESO-1%20vaccine%20combined%20with%20poly-ICLC%20in%20advanced%20or%20recurrent%20esophageal%20cancer%20patients&rft.jtitle=Cancer%20Immunology,%20Immunotherapy&rft.au=Ishikawa,%20Takeshi&rft.date=2021-11-01&rft.volume=70&rft.issue=11&rft.spage=3081&rft.epage=3091&rft.pages=3081-3091&rft.issn=0340-7004&rft.eissn=1432-0851&rft_id=info:doi/10.1007/s00262-021-02892-w&rft_dat=%3Cproquest_pubme%3E2580827446%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2580827446&rft_id=info:pmid/33751208&rfr_iscdi=true |